Table 3.

Recommended criteria for the administration of the currently available EUA-approved COVID-19 vaccines (BioNTech and Moderna COVID-19 vaccines) during pregnancy if one or more of the listed conditions is met using the Interim Clinical Considerations for use of the mRNA COVID-19 vaccines currently utilized in the United States

•Healthcare providers

•Women aged ≥35 y

•Multiple gestation

•Cancer

•Chronic hypertension

•Chronic kidney disease

•Chronic obstructive pulmonary disease

•Heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies

•Immunocompromised state (weakened immune system) from solid organ transplant

•Autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, graves’ disease, psoriasis or psoriatic arthritis, Addison’s disease

•Obesity (body mass index of 30 kg/m2 or higher)

•Sickle cell disease

•Smoking (current or history)

•Type 1 or 2 diabetes mellitus

Contraindications: severe allergic reaction (eg, anaphylaxis) after a previous dose of an mRNA COVID-19 vaccine or any of its components.

Immediate allergic reaction of any severity to a previous dose of an mRNA COVID-19 vaccine or any of its components (including PEG).

Immediate allergic reaction of any severity to polysorbate (because of potential cross-reactive hypersensitivity with the vaccine ingredient (PEG).

COVID-19, coronavirus disease 2019; EUA, Emergency Use Administration; PEG, polyethylene glycol.

Adapted from the Centers for Disease Control and Prevention.¹¹⁶

Stafford. The coronavirus disease 2019 vaccine in pregnancy. Am J Obstet Gynecol 2021.